文献速递腹部MR

VICT2特征:肝细胞癌瘤周肝胆期低信号的预后替代指标

VICT2 Trait: Prognostic Alternative to Peritumoral Hepatobiliary Phase Hypointensity in HCC.
PubMed 文献 · Radiology · 2023-02-14

本研究回顾性纳入660例肝细胞癌患者,基于四种非肝胆特异性MRI特征构建VICT2特征,其预测微血管侵犯和术后无复发生存的价值与瘤周肝胆期低信号相当,且在EOB组对MVI特异性更高(89% vs 80%)。

要点

  • VICT2特征由瘤周门静脉期低强化、包膜不完整、晕环强化和瘤周轻中度T2高信号组成。
  • VICT2特征预测MVI的OR为5.1,预测RFS的HR为2.3,与瘤周HBP低信号预后价值相当。
  • 在非肝胆特异性对比剂增强MRI中也可应用VICT2特征评估HCC预后。

关键影像表现/征象

  • 瘤周门静脉期低强化(OR=8.8)、包膜不完整(OR=3.3)、晕环强化(OR=2.6)和瘤周轻中度T2高信号(OR=2.2)与瘤周肝胆期低信号相关(均P<.001)。
  • 上述四种征象构成VICT2特征,测试集AUC为0.84(95%CI:0.78,0.90)。

诊断标准与关键数值

  • VICT2特征预测MVI的OR=5.1(P<.001),预测RFS的HR=2.3(P<.001)。
  • 瘤周肝胆期低信号预测MVI的OR=2.5(P=.02),预测RFS的HR=2.5(P<.001)。
  • VICT2特征对MVI的特异性高于瘤周肝胆期低信号(89% vs 80%,P=.01)。
  • 在细胞外对比剂组中,VICT2特征预测MVI的OR=4.0,预测RFS的HR=1.7(均P<.001)。

临床应用与阅片要点

  • 在非肝胆特异性增强MRI中,可依据瘤周门静脉期低强化、包膜不完整、晕环强化和瘤周轻中度T2高信号识别VICT2特征。
  • VICT2特征可用于术前评估HCC的MVI风险和术后复发风险。
  • VICT2特征对MVI的特异性高于瘤周肝胆期低信号,有助于减少假阳性。

局限性

  • 本研究为回顾性单中心设计。
  • VICT2特征基于特定人群构建,外部验证有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Peritumoral hepatobiliary phase (HBP) hypointensity is an established prognostic imaging feature in hepatocellular carcinoma (HCC), often associated with microvascular invasion (MVI). Similar prognostic features are needed for non-HBP MRI. Purpose To propose a non-hepatobiliary-specific MRI tool with similar prognostic value to peritumoral HBP hypointensity. Materials and Methods From December 2011 to November 2021, consecutive patients with HCC who underwent preoperative contrast-enhanced MRI were retrospectively enrolled and followed up until recurrence. All MRI scans were reviewed by two blinded radiologists with 7 and 10 years of experiences with liver MRI. A scoring system based on non-hepatobiliary-specific features that highly correlated with peritumoral HBP hypointensity was identified in a stratified sampling-derived training set of the gadoxetate disodium (EOB) group by means of multivariable logistic regression, and its values to predict MVI and recurrence-free survival (RFS) were assessed. Results There were 660 patients (551 men; median age, 53 years; IQR, 45-61 years) enrolled. Peritumoral portal venous phase hypoenhancement (odds ratio [OR] = 8.8), incomplete "capsule" (OR = 3.3), corona enhancement (OR, 2.6), and peritumoral mild-moderate T2 hyperintensity (OR, 2.2) (all P < .001) were associated with peritumoral HBP hypointensity and constituted the "VICT2 trait" (test set area under the receiver operating characteristic curve = 0.84; 95% CI: 0.78, 0.90). For the EOB group, both peritumoral HBP hypointensity (OR for MVI = 2.5, P = .02; hazard ratio for RFS = 2.5, P < .001) and the VICT2 trait (OR for MVI = 5.1, P < .001; hazard ratio for RFS = 2.3, P < .001) were associated with MVI and RFS, despite a higher specificity of the VICT2 trait for MVI (89% vs 80%, P = .01). These values of the VICT2 trait were confirmed in the extracellular contrast agent group (OR for MVI = 4.0; hazard ratio for RFS = 1.7; both P < .001). Conclusion Based on four non-hepatobiliary-specific MRI features, the VICT2 trait was comparable to peritumoral hepatobiliary phase hypointensity in predicting microvascular invasion and postoperative recurrence of hepatocellular carcinoma. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Harmath in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Jiang, Wei, Yang, et al. VICT2 Trait: Prognostic Alternative to Peritumoral Hepatobiliary Phase Hypointensity in HCC. Radiology. 2023. PMID: 36786702. doi:10.1148/radiol.221835

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。